NLS Pharmaceutics Analyst Ratings
NLS Pharmaceutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 933.24% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1966.47% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 1277.65% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/08/2022 | — | Maxim集團 | 評級下調 | 購買→Hold | |
| 09/06/2022 | 933.24% | 萊德勞公司 | → $6 | 開始承保 | →購買 |
| 03/12/2021 | 1966.47% | 布魯克林資本 | → $12 | 開始承保 | →購買 |
| 03/03/2021 | 1277.65% | Maxim集團 | → $8 | 開始承保 | →購買 |
NLS Pharmaceutics Questions & Answers
NLS製藥問題與解答
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on November 8, 2022. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
馬克西姆集團於2022年11月8日報道了NLS製藥公司(納斯達克代碼：NLSP)的最新目標價。這家分析公司將目標價定為0.00美元，預計NLSP將在12個月內降至(可能下跌-100.00%)。去年有兩家分析公司公佈了評級。
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.
新星醫藥(納斯達克代碼：NLSP)的最新分析師評級由Maxim Group提供，新星製藥下調了其持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與NLS製藥公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。NLS製藥的上一次評級是在2022年11月8日提交的，所以你應該預計下一次評級將在2023年11月8日左右提供。
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.58, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的NLS製藥(NLSP)評級被下調，目標價為0.00美元至0.00美元。NLS製藥公司(NLSP)目前的交易價格為0.58美元，超出了分析師的預測區間。